Recursion Pharmaceuticals, Inc. Class A

XNASHealth care

Last traded price · USD

$3.59

−7.48%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:43 IST · A quote does not mean the product is available to trade on your account.

Day's open: $3.79
Previous close: $3.88
Volume: 5.0M
Day's high: $3.80
Day's low: $3.55

In brief

Recursion Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $2.15B.
Its shares closed at $3.88 on 4 Nov 2026, down 22.4% over the past year.
From India you can buy RXRX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Recursion Pharmaceuticals, Inc. (RXRX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole RXRX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade RXRX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −16.2% (SPY −1.6%, XLV +13.5%). 3 months: +22.4% (SPY −0.4%, XLV +15.5%). 1 year: −22.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RXRX, SPY and XLV · as of 4 Nov 2026
Short interest at 30.2% of shares outstanding
161.9M shares were sold short at the 15 Oct 2026 settlement, 30.2% of the 535.3M shares outstanding; covering them would take 4.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $3.88 was 3.0% above its 50-day average ($3.77) and 10.4% above its 200-day average ($3.52). It has closed above the 200-day for 13 sessions, since 19 Oct 2026. The 50-day average crossed above the 200-day on 12 Oct 2026, 17 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
45% of the way up its 52-week range
Closed at $3.88 on 4 Nov 2026: 26.0% below the 52-week high of $5.24 (22 Jan 2026) and 40.1% above the low of $2.77 (19 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−16.2%

6 months+13.1%

1 year−22.4%

5 years−80.1%

Newswire

About

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

Website

Notable moves

April 11, 2025
+27.72%
July 12, 2023
+78.17%
May 22, 2023
+26.28%

Recursion Pharmaceuticals, Inc. Class A

XNASHealth care

Last traded price · USD

$3.59

−7.48%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:43 IST · A quote does not mean the product is available to trade on your account.

Day's open: $3.79
Previous close: $3.88
Volume: 5.0M
Day's high: $3.80
Day's low: $3.55

In brief

Recursion Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $2.15B.
Its shares closed at $3.88 on 4 Nov 2026, down 22.4% over the past year.
From India you can buy RXRX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Recursion Pharmaceuticals, Inc. (RXRX) shares from India?

Do I need the price of a whole RXRX share to invest?

How much can I invest in US stocks in a year?

Can I trade RXRX options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −16.2% (SPY −1.6%, XLV +13.5%). 3 months: +22.4% (SPY −0.4%, XLV +15.5%). 1 year: −22.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RXRX, SPY and XLV · as of 4 Nov 2026
Short interest at 30.2% of shares outstanding
161.9M shares were sold short at the 15 Oct 2026 settlement, 30.2% of the 535.3M shares outstanding; covering them would take 4.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $3.88 was 3.0% above its 50-day average ($3.77) and 10.4% above its 200-day average ($3.52). It has closed above the 200-day for 13 sessions, since 19 Oct 2026. The 50-day average crossed above the 200-day on 12 Oct 2026, 17 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
45% of the way up its 52-week range
Closed at $3.88 on 4 Nov 2026: 26.0% below the 52-week high of $5.24 (22 Jan 2026) and 40.1% above the low of $2.77 (19 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−16.2%

6 months+13.1%

1 year−22.4%

5 years−80.1%

Newswire

About

Website

Notable moves

April 11, 2025
+27.72%
July 12, 2023
+78.17%
May 22, 2023
+26.28%

Recursion Pharmaceuticals, Inc. Class A

Recursion Pharmaceuticals, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Short interest at 30.2% of shares outstanding

Above its 50- and 200-day averages

45% of the way up its 52-week range

Recursion Pharmaceuticals, Inc. Class A

Recursion Pharmaceuticals, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Short interest at 30.2% of shares outstanding

Above its 50- and 200-day averages

45% of the way up its 52-week range